Two episodes of hypotension caused by oral beraprost sodium administration following cardiac surgery are described. The first case was a 67-year-old female who underwent concomitant surgery for mitral valve replacement, tricuspid annuloplasty, and a radiofrequency maze procedure for atrial fibrillation. The second case was a 45-year-old female who underwent 4-vessel coronary artery bypass grafting associated with endarterectomy in the right coronary artery. Beraprost sodium was administered for the treatment of residual pulmonary hypertension in the first case, and was initiated as an antiplatelet agent following coronary endarterectomy in the second case. Hypotension occurred at approximately one hour after beraprost sodium administration in both cases. Careful observation to prevent this adverse effect is critical after the administration of beraprost sodium, especially in patients who have undergone cardiac surgery. (Int Heart J 2006; 47: 319-323) Key words: Beraprost sodium, Prostacyclin, Hypotension, Cardiac surgery PROSTACYCLIN (PGI 2 ) and its analogues are potent vasodilators and possess antithrombotic and antiproliferative properties. Beraprost sodium, an oral prostacyclin analogue, has among other effects antiplatelet and vasodilating effects, which have been widely used for patients with pulmonary hypertension and chronic arterial occlusive disease. We describe here 2 episodes of hypotension induced by oral beraprost sodium administration following cardiac surgery, and discuss the clinical use of beraprost sodium and the etiology of this adverse phenomenon.
and atrial fibrillation. The patient was grade 3 according to the New York Heart Association (NYHA) functional classification. Cardiomegaly (cardiothoracic ratio, 64%), pulmonary hypertension, reduced cardiac output, and low %vital capacity (73%) were observed in preoperative evaluation (Table) . The patient had insulin-dependent diabetes mellitus. She underwent concomitant surgery consisting of mitral valve replacement, tricuspid annuloplasty, and a radiofrequency maze procedure for atrial fibrillation. After surgery, cardiac failure associated with pulmonary hypertension remained, and intravenous infusion of diuretics, catecholamine, milrinon, and human natriuretic peptide was continued. An endotracheal tube was extubated on postoperative day 8, followed by nasal mask bilevel positive airway pressure (BiPAP) support. On the 21 st day after surgery, 40
µg of beraprost sodium was administered concomitantly with the weaning of intravenous milrinon. Before beraprost administration, no inotropic drug was infused and sinus rhythm was maintained after the radiofrequency maze procedure. Approximately one hour after beraprost sodium administration, systolic blood pressure decreased from 100 to 70 mmHg. Blood pressure recovered after the initiation of intravenous dopamine and volume loading. Central venous pressure before beraprost sodium administration was 4 mmHg. Case 2: A 45-year-old female was diagnosed as having severe coronary artery disease and chronic heart failure. She was grade 3 according to the NYHA functional classification. Coronary angiograms revealed severe triple vessel disease. Both impaired left ventricular function (ejection fraction: 0.41) and renal dysfunction (serum creatinine: 1.7 mg/dL) were observed in preoperative evaluations (Table) . The patient had insulin-dependent diabetes mellitus and nephrosis, and had undergone 4-vessel coronary artery bypass grafting associated with endarterectomy in the right coronary artery. After surgery, her respiratory condition was stable and the endotracheal tube was removed on the same day of the operation. Her circulatory condition was well maintained using intravenous dopamine and dobutamine infusion (3 µg/kg/min, respectively), and the cardiac index ranged from 3.3 to 3.6 L/min/m 2 . On the 2nd day after surgery, 40 µg of beraprost sodium was given as an antiplatelet agent after coronary artery endarterectomy. Approximately one hour after beraprost sodium administration, her systolic blood pressure decreased from 120 to 68 mmHg. Systolic pulmonary artery pressure increased from 20 to 28 mmHg. The patient complained of nausea and experienced vomiting. Blood pressure recovered after increasing intravenous catecholamine and volume loading (Figure) .
DISCUSSION
Prostacyclin has been the only drug with antiproliferative and vascular remodeling activity available for the treatment of primary pulmonary arterial hypertension (PAH). 1) Beraprost sodium, an oral prostacyclin analogue, has been used mainly for the treatment of 2 pathological conditions: primary PAH and chronic arterial occlusive disease. Oral administration of beraprost sodium may result in long-lasting clinical and haemodynamic improvements in patients with severe PAH.
2) Beraprost sodium has also been shown to improve exercise capacity and symptoms in NYHA functional class II and III patients with PAH. 3) Durongpisitkul, et al reported beraprost has a pulmonary vasodilating effect similar to that of inhaled nitric oxide (iNO) and can be used as an acute pulmonary vasodilating agent. 4) Abnormal biosynthesis of thromboxane and prostacyclin has been implicated in patients with primary pulmonary hypertension and secondary pulmonary hypertension associated with congenital heart disease. Beraprost improved the imbalance of thromboxane and prostacyclin biosynthesis and has a potential application for preventing the progressive development of pathological changes in pulmonary vasculature. 5) Similar to the treatment of severe primary PAH, beraprost sodium therapy improved NYHA functional class, hemodynamics, and hormonal parameters in patients with secondary precapillary PAH. 6) In our first case, cardiac failure associated with PAH remained after surgically treating the mitral valve disease which had a long history, thus, we adopted beraprost sodium in order to improve the secondary PAH.
Beraprost sodium has been reported to exhibit beneficial effects on atherosclerosis in both human and animal models. Beraprost sodium inhibits neointimal formation after balloon denudation in the coronary artery due to its inhibitory effect on SMC proliferation by preventing p27 (Kip1) down-regulation. 7) In our second case, the postoperative hemodynamic condition was fair, and beraprost sodium was used for maintenance after coronary artery bypass grafting associated with endarterectomy. Ueno, et al reported that beraprost had a cytoprotective effect and also suppressed reperfusion arrhythmia, plasma creatine phosphokinase (CK), and lactate dehydrogenase (LDH) levels due to the reduction of neutrophil migration during myocardial ischemia and reperfusion. According to the pharmacopoeia, shock after oral intake of beraprost sodium is relatively rare and occurs in less than 0.1% of patients. In the first case, we could not readily define the cause of the hypotension. After experiencing the second case, we recognized that the circulatory collapse was caused by beraprost sodium. Hypotension occurred at approximately one hour after beraprost sodium administration in both cases. The adverse effects of prostacyclin and its analogues largely depend on the doses used and the mode of application. 9) We initiated beraprost sodium with a typical dosage (120 µg /day), however, this typical initial dosage should be reduced in patients after cardiac surgery. Oral administration is generally considered to be a safe route, however, careful observation to prevent this adverse effect is critical after the administration of beraprost sodium. Central venous pressure prior to beraprost sodium administration was 4 and 3 mmHg in each case. This hypovolemic condition might have been one of the causes of the shock. Heart rates did not increase after hypotension, thus, autonomic disorder due to diabetes mellitus or the postoperative cardiac condition was conceivable. No drug known to have a positive interaction with beraprost was administered in either case. Further research is needed in order to determine which patients will benefit most from administration of beraprost sodium, and its appropriate dosages.
